HC Wainwright & Co. Reiterates Buy on TransCode Therapeutics, Maintains $3 Price Target

Benzinga · 05/29 16:34
HC Wainwright & Co. analyst Emily Bodnar reiterates TransCode Therapeutics (NASDAQ:RNAZ) with a Buy and maintains $3 price target.